Compare Biogen Inc (BIIB) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Devon Energy Corp — how do they compare? Biogen Inc trades at $207.13 (market cap $30.13B), while Devon Energy Corp trades at $45.06 (market cap $49.94B). The key difference: Devon Energy Corp is the larger of the two by market cap, and Devon Energy Corp pays a 2.82% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DVN | |
|---|---|---|
Market Cap | $30.13B | $49.94B |
Sector | Health | Energy |
52-Week High | $216.63 | $52.07 |
52-Week Low | $128.93 | $31.74 |
Enterprise Value | $37.20B | $60.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Devon Energy (DVN) trades at $44.93, down 0.95% on the day, amid a bullish technical signal and strong Q2 2026 earnings that beat estimates. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil production. Valuation ratios remain attractive with a P/E of 9.87 and EV/EBITDA of 6.89. Recent news highlights a 33% dividend hike and accelerated debt reduction, reinforcing positive sentiment.
The outlook for DVN is positive, supported by robust free cash flow, shareholder returns, and operational execution. Key opportunities include synergy realization from the Coterra merger and a consensus price target of $61.91. Risks involve oil price volatility and integration challenges. Wall Street sentiment is strongly bullish with 71% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
